Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Inflammation01:38

Inflammation

46.6K
Overview
46.6K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

2.5K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.5K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

659
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
659

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Authors' response.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Safety and efficacy of three office-based egg oral immunotherapy protocols.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Eosinophilic esophagitis incidence during single and multiple food oral immunotherapy.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Retraction notice to "Present trends, sustainable strategies and energy potentials of crop residue management in India: A review" [Heliyon 10 (2024) e39815].

Heliyon·2025
Same author

Differential effects of sole and phosphorus based nitrogen fertilizer sources on wheat growth and nutrient use efficiency.

Scientific reports·2025
Same author

Impact of Growth-Promoting Endophytic Bacteria on Ginger Plant Growth.

Indian journal of microbiology·2025

相关实验视频

Updated: May 4, 2026

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

13.0K

聚 ((ADP-ribose) 聚合酶抑制降低了动脉样硬化斑块的大小,并促进了非脂蛋白E缺陷小鼠中的斑块稳定性因素:对巨细胞招募,核因子-kappaB核转移和泡细胞死亡的影响.

Karine Oumouna-Benachour1, Chetan P Hans, Yasuhiro Suzuki

  • 1Louisiana State University Health Sciences Center, Department of Pharmacology, 1901 Perdido St, New Orleans, LA 70112, USA.

Circulation
|April 18, 2007
PubMed
概括
此摘要是机器生成的。

在小鼠中,Poly ((ADP-ribose) 聚合酶 (PARP) 抑制减少了动脉样硬化斑块的发育和大小. 这表明PARP抑制可能对治疗动脉样硬化和促进斑块稳定有益.

更多相关视频

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

9.7K
Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

41.6K

相关实验视频

Last Updated: May 4, 2026

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

13.0K
Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

9.7K
Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

41.6K

科学领域:

  • 心血管研究研究心血管研究
  • 分子生物学分子生物学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 聚 ((ADP-ribose) 聚合酶 (PARP) 与与心血管疾病相关的内皮功能障碍有关.
  • PARP在动脉动脉产生中的作用及其作为动脉样硬化治疗点的潜力需要进一步研究.

研究的目的:

  • 研究PARP在动脉样硬化发展中的作用.
  • 确定PARP抑制是否可以减轻动脉样硬化斑块的进展并改善斑块的稳定性.

主要方法:

  • 在高脂肪饮食中的Apolipoprotein E淘汰赛 (ApoE-/-) 小鼠被用于模拟动脉样硬化.
  • 使用小分子 thieno[2,3-c]isoquinolin-5-one.one 实现了 PARP 抑制.
  • 基因研究涉及对PARP-1和PARP-1淘汰赛巨细胞异合体的ApoE-/-小鼠.

主要成果:

  • 在动脉样硬化斑块内观察到PARP激活,与细胞死亡和氧化应激相关.
  • 抑制PARP可以减少斑块数量和大小,增加原蛋白含量,并促进平滑肌肉细胞的转移.
  • 抑制PARP降低了单细胞化疗蛋白-1的产生,并保护泡细胞免于死亡,将其从亡转移到亡.

结论:

  • 抑制PARP会干扰动脉样硬化斑块的发展,并可能增强斑块的稳定性.
  • 减少炎症因素和改变细胞动力学有助于PARP抑制的保护作用.
  • 抑制PARP是一种有前途的治疗策略,用于治疗动脉样硬化.